Skip to main content
Equibles

David A. Lamond

Chairman

Quince Therapeutics, Inc. (QNCX)

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About David A. Lamond

David A. Lamond is recorded as Chairman at Quince Therapeutics, Inc. (QNCX). Quince Therapeutics, Inc. reported in an 8-K filed October 9, 2026 that David A. Lamond resigned as director, effective October 8, 2026. Quince Therapeutics, Inc. reported in an 8-K filed October 2, 2026 that David A. Lamond resigned as Director.

“As previously announced, effective as of October 8, 2026, June Bray, David Lamond, Christopher Senner, and Mr. Thye resigned from the Board.”
Quince Therapeutics, Inc. Form 8-K, filed October 9, 2026 · Read the filing
“On September 30, 2026, each of June Bray, David Lamond and Christopher Senner (collectively, the “Resigning Directors”) tendered conditional resignations from the Board of Directors (the “Board”) of Quince Therapeutics, Inc. (the “Company”), in each case effective as of two business days following the conclusion of the Company’s Special Meeting of Stockholders, which will be held on October 6, 2026 (the “Special Meeting”), and contingent upon the approval by the Company’s stockholders of the following three proposals to be presented at the Special Meeting (the “Effective Time”)”
Quince Therapeutics, Inc. Form 8-K, filed October 2, 2026 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Quince Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.